These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

999 related articles for article (PubMed ID: 33581502)

  • 1. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1/PD-1 Axis in Glioblastoma Multiforme.
    Litak J; Mazurek M; Grochowski C; Kamieniak P; Roliński J
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
    Yang T; Kong Z; Ma W
    Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
    Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
    Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
    Sanders S; Debinski W
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.
    Pearson JRD; Puig-Saenz C; Thomas JE; Hardowar LD; Ahmad M; Wainwright LC; McVicar AM; Brentville VA; Tinsley CJ; Pockley AG; Durrant LG; McArdle SEB
    Cancer Immunol Immunother; 2024 Jul; 73(9):178. PubMed ID: 38954031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
    Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
    Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.
    Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H
    Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth.
    Yan Z; Huang L; Zhang X; Yu X; Huang R
    Sci Rep; 2024 Aug; 14(1):18444. PubMed ID: 39117725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).
    Wu J; Wang N
    Mol Med Rep; 2024 Dec; 30(6):. PubMed ID: 39364736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.